Glycaemic control and macrovascular and microvascular outcomes in type 2 diabetes: systematic review and meta-analysis of cardiovascular outcome trials of novel glucose-lowering agents
Collins R et al.: Interpretation of the evidence for the efficacy and safety of statin therapy
Several GLP-1R peptide-based agonists including liraglutide, semaglutide, dulaglutide, and tirzepatide (a dual GLP-1R/GIPR agonist) have been approved for the treatment of obesity and type 2 diabetes, achieving unprecedented improvements in glycemic control and body weight reduction (Arslanian et al., 2022
Graves disease is a medical condition that can affect individuals from all walks of life, including famous personalities
Mounjaro (tirzepatide) is a medication within this group that activates both the GLP-1 and GIP (glucose-dependent insulinotropic polypeptide) receptors
Checking multiple pharmacies and online programs may reveal better pricing options for GLP-1 medications
